TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06024109

Intervention type: DEVICE
Intervention: Closure of the Vaginal Cuff after Total Hysterectomy
Description: Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).

Intervention type: DEVICE
Intervention: Closure of the Vaginal Cuff after Total Hysterectomy
Description: Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
Study: NCT05031299

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-promotion application for self-management
Description: Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
Study: NCT06279962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.
Study: NCT05031299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearables and devices
Description: Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
Study: NCT06279962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.
Study: NCT04821921

Intervention type: OTHER
Intervention: No intervention
Description: Care as usual
Study: NCT05645107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xembify
Description: SC infusion pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC infusion pump
Study: NCT05634785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATLCAR.CD30 Cells
Description: The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
Study: NCT05828589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: BGB-21447 will be administered orally
Study: NCT06471452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interaktor
Description: In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal.
Study: NCT06072729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison of magnesium sulphate versus cold compression
Description: This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison of magnesium sulphate versus cold compression
Description: This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
Study: NCT05828589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: BGB-21447 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-21447
Description: BGB-21447 will be administered orally
Study: NCT06224140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Anticoagulation
Description: Conventional dialysis with heparin as anticoagulant treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anticoagulation Procedure (RAP)
Description: Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
Study: NCT05812963

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI group
Description: In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided PCI group
Description: In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
Study: NCT05626140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 50 MG Oral Tablet [Vimpat]
Description: Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate
Description: Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study: NCT05265390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescents watching an informational video
Description: In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
Study: NCT05626140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study: NCT04931797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: advance care planning video decision aid

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control arm ACP information sheet
Description: control arm ACP information sheet
Study: NCT04997161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
Study: NCT04731194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based financial incentive program
Description: 1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy.
Study: NCT04997161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced dietary advice
Description: Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
Study: NCT05007418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-1492
Description: Anti-CD38 A2 KOKI DAR T cells
Study: NCT04997161

Intervention type: OTHER
Group type: OTHER
Intervention: Standard dietary advice including K+ restriction.
Description: Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
Study: NCT05827328

Intervention type: OTHER
Intervention: Observation
Description: Observe the 30-day mortality and 30-day morbidity.
Study: NCT04678362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib + Avelumab
Description: Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
Study: NCT06409871

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy treatment.
Description: -Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment and modification of the biorhythm.
Description: * Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime.
Study: NCT06164678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OMSC
Description: The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
Study: NCT04807608

Intervention type: OTHER
Intervention: Usability Assessment
Description: A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
Study: NCT05399589

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: use on1 abutment instead of healing cap in test group
Description: We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: use healing cap in control group
Description: use healing cap in control group
Study: NCT05199636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dragon fruit product
Description: Frozen dragon fruit based beverage
Study: NCT05790018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREGNANT PILLOW
Description: First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
Study: NCT06652412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafractionated RT and CGA Guided systemic treatment.
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.

Intervention type: OTHER
Group type: OTHER
Intervention: data prospectively collected
Description: in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated Radiotherapy
Description: 1Fx every 3 or 4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil or capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: irinotecan
Study: NCT05384990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance Electric Stimulation
Description: Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
Study: NCT06380036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video assisted fistula tract surgery
Description: in one group pt recieved VAAFTS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video assisted fistula tract surgery
Description: in one group pt recieved VAAFTS
Study: NCT06659211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalisation-Based Therapy
Description: MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
Study: NCT06221943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Naturalistic Developmental Behavioral Intervention
Description: Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Naturalistic Developmental Behavioral Intervention
Description: Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
Study: NCT05404945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 25mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 25mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6mg/m2 IV
Study: NCT06221943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASD Diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASD Diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study: NCT06245304

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual chamber Medtronic pacemaker implantation.
Description: All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830.

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual chamber Medtronic pacemaker implantation.
Description: All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830.

Intervention type: OTHER
Group type: OTHER
Intervention: DDD-50 pacing program
Description: This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
Study: NCT05404945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: Vinblastine 6mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: Vinblastine 6mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 375mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 375mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine 375mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin 1.8 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin 1.8 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin 1.8 mg/kg IV
Study: NCT06245304

Intervention type: OTHER
Group type: OTHER
Intervention: DDD-50 pacing program
Description: This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
Study: NCT06112080

Intervention type: DEVICE
Intervention: RESP™ Biosensor
Description: The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.

Intervention type: DEVICE
Intervention: RESP™ Biosensor
Description: The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
Study: NCT06245304

Intervention type: OTHER
Group type: OTHER
Intervention: AAI-DDD 50 pacing program
Description: This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.

Intervention type: OTHER
Group type: OTHER
Intervention: AAI-DDD 50 pacing program
Description: This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.